2024-02-26

Clinical Recruitment: 45 Patients with Ischemic Stroke

China's first Phase I/IIa clinical trial (ASSIST) for treating ischemic stroke using imported stem cells, led by Jiuzhitang Maker, is now recruiting 45 voluntary participants who have experienced ischemic stroke to join the Phase IIa study.

2023-12-11

Latest research finding: Bone marrow mesenchymal stem cells can significantly improve behavioral deficits in mice with autism.

On December 3, 2023, Jiuzhitang Maker’s preclinical pharmacodynamic study titled "Intravenous transplantation of bone marrow-derived mesenchymal stem cells improved behavioral deficits and altered fecal microbiota composition of BTBR mice," which explores the use of human bone marrow mesenchymal stem cells (hBMMSC) to treat autism, was officially accepted and published in the internationally renowned academic journal *Life Sciences*.

2023-12-11

Jiuzhitang Maker named to Huayi List's "Top 10 Most Promising Stem Cell Companies" list

On December 7-8, 2023, the highly anticipated "Huayi List · 2023 Cell and Gene Therapy Industry Visionary Ranking," jointly launched by YiYun Technology, Pinhe Medical, and BioValley, was officially unveiled. Jiuzhitang Maker was named among the "Top 10 Most Promising Stem Cell Companies" on the Huayi List.

2023-11-23

The key laboratory in Hunan Province, jointly established by Jiuzhitang Maker, officially kicks off operations.

Jiuzhitang Maker's participation in establishing the Hunan Provincial Key Laboratory is a strong recognition of the company's deep expertise and groundbreaking research achievements in stem-cell-based pharmaceutical quality. It also highlights the critical R&D direction for stem-cell products in the pharmaceutical field. Moving forward, Jiuzhitang Maker will fully leverage its cutting-edge stem-cell research capabilities to drive innovation and accelerate clinical translation of stem-cell technologies, continuously fueling the high-quality development of the Hunan Provincial Key Laboratory.

2023-11-04

The Phase IIa clinical trial kickoff meeting for Jiuzhitang Maker's stem cell therapy targeting rare lung diseases was successfully held.

On November 1, 2023, the kickoff meeting for the clinical trial of human bone marrow mesenchymal stem cell injection therapy for a rare lung disease—autoimmune alveolar proteinosis (aPAP)—co-sponsored by Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereafter referred to as "Jiuzhitang Maker") and the First Affiliated Hospital of Guangzhou Medical University (hereafter referred to as "Guangyi Yiyuan"), was successfully held. Academician Zhong Nanshan attended the entire event and provided guidance throughout the trial.

2023-07-20

Jiuzhitang Maker's bone marrow mesenchymal stem cell product has passed the comprehensive quality testing by the National Institute for Food and Drug Control.

Recently, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereafter referred to as "Jiuzhitang Maker") received inspection reports from the China Institute of Food and Drug Control (hereafter referred to as "CIFDC"), confirming that human bone marrow mesenchymal stem cell products sourced from different donors and produced in various batches all met the required quality standards.

2023-07-20

Great news! The key laboratory in Hunan Province, established with the participation of Jiuzhitang Maker, has been approved!

Recently, according to the relevant provisions of the "Management Measures for the Construction and Operation of Key Laboratories in Hunan Province" (Hunan Science and Technology Development [2022] No. 173), 22 key laboratories in Hunan Province have been officially announced following procedures including organizational recommendations, expert consultations, and committee reviews. Among them is the "Hunan Provincial Key Laboratory for Critical Quality Attributes of Cell Therapy Products," which Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.—the stem-cell pharmaceutical enterprise under Jiuzhitang—has helped establish.

2023-07-20

Jiuzhitang Maker's latest stem-cell drug has received IND approval for clinical trials!

On June 9, 2023, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as "Jiuzhitang Maker") received implicit approval from the National Medical Products Administration for its Investigational New Drug (IND) application—specifically, for the "Human Bone Marrow Mesenchymal Stem Cell Injection"—for clinical trials targeting autoimmune alveolar proteinosis (aPAP). This marks the first-ever IND submission in China exploring stem cell therapy for aPAP, offering promising new hope for patients suffering from this debilitating condition.

2023-04-12

Jiuzhitang Maker attends the Stem Cell Summit Workshop

As a leading force in the field of clinical stem cell research and a member organization of the China Association for Medical Biotechnology, Dr. Gao Yansong, General Manager of Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereafter referred to as "Jiuzhitang Maker"), was invited to attend this prestigious event. There, he joined key officials responsible for stem cell clinical research management across the country, along with renowned experts in the field, as well as representatives from stem cell clinical research institutions, stem cell product development firms, and financial and investment organizations, to collectively learn from and discuss the latest advancements in China’s stem cell clinical research achievements.